chymotrypsin
Trade name: zolyse
Approved
May 29, 1959
Chymotrypsin (EC 3.4.21.1, chymotrypsins A and B, alpha-chymar ophth, avazyme, chymar, chymotest, enzeon, quimar, quimotrase, alpha-chymar, alpha-chymotrypsin A, alpha-chymotrypsin) is a digestive enzyme component of pancreatic juice acting in the duodenum, where it performs proteolysis, the breakdown of proteins and polypeptides. Chymotrypsin preferentially cleaves peptide amide bonds where the side chain of the amino acid N-terminal to the scissile amide bond (the P1 position) is a large hydrophobic amino acid (tyrosine, tryptophan, and phenylalanine). These amino acids contain an aromatic ring in their side chain that fits into a hydrophobic pocket (the S1 position) of the enzyme. It is activated in the presence of trypsin. The hydrophobic and shape complementarity between the peptide substrate P1 side chain and the enzyme S1 binding cavity accounts for the substrate specificity of this enzyme. Chymotrypsin also hydrolyzes other amide bonds in peptides at slower rates, particularly those containing leucine at the P1 position. — Wikipedia
Clinical trial activity
3 trials · 4 clinical orgs · 4 marketing orgs
Earliest trial started Jun 8, 2022 (NCT06139835)
Timeline
1950s
- May 29, 1959
Earliest FDA Approval
- May 29, 1959
Johnson and Johnson — NDA Secondary Org
- Jul 8, 1959
Alcon — First NDA Organization
- Jul 8, 1959
Alcon — NDA Secondary Org
- Jul 8, 1959
Alcon — NDA Organization
1970s
- Mar 27, 1979
Novartis — NDA Secondary Org
Indications
Approved for
Studied for
Mechanism of action
- PolypeptidesPROTEOLYTIC ENZYME
Polypeptides proteolytic enzyme
To replace endogenous digestive enzyme chymotrypsin, which protects against pancreatitis, in cases where loss of function variants have been identified in the CTRC gene; preferential cleavage: leu-|-xaa, tyr-|-xaa, phe-|-xaa, met-|-xaa, trp-|-xaa, gln-|-xaa, asn-|-xaa.
Approval history
- approvedMay 29, 1959
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Discontinued
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaChymotrypsin ↗
- NCATSBVS505O332 ↗
- ChEMBLCHEMBL1201465 ↗
Also known as
- alpha chymar
- alpha chymar
- alpha-chymar
- catarase
- chymar
- chymoral
- chymoral
- chymoral fte
- chymotrypsin
- chymotrypsin
- chymotrypsin
- chymotrypsin
- chymotrypsin
- chymotrypsin
- chymotrypsin
- chymotrypsin - trypsin
- chymotrypsin, trypsin drug combination
- chypsin
- deanase dc
- ec 3.4.21.1
- zolyse
- zolyse
- zonulysin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06562816 | Phase 4 | Aug 16, 2024 | Dow University of Health Sciences, Duke University |
| NCT06164509 | Phase 4 | Dec 20, 2023 | Ain Shams University |
| NCT06139835 | N/A | Jun 8, 2022 | Pontis Biologics, Inc. |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ain Shams University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Dow University of Health Sciences | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Pontis Biologics, Inc. | For profit | 1 | 1 | 1 | 2022 |
Marketing (5)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Alcon | For profit | NDA2 | Jul 8, 1959 |
| Alcon | For profit | NDA | Jul 8, 1959 |
| Ciba | For profit | NDA2 | — |
| Johnson and Johnson | For profit | NDA2 | May 29, 1959 |
| Novartis | For profit | NDA2 | Mar 27, 1979 |